This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/resource/domain/vavai/subjekt/
n13http://linked.opendata.cz/ontology/domain/vavai/
n8http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F11%3A%230001362%21RIV12-MZ0-65269705/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F65269705%3A_____%2F11%3A%230001362%21RIV12-MZ0-65269705
rdf:type
skos:Concept n13:Vysledek
dcterms:description
AB An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM). On the basis of the available evidence, the panel agreed that Len/Dex is a valid and effective treatment option for most patients with RRMM. As with other therapies, using Len/Dex at first relapse is more effective regarding response rate and durability than using it after multiple salvage therapies. Len/Dex may be beneficial regardless of patient age, disease stage and renal function, although the starting dose of lenalidomide should be adjusted for renal impairment and cytopenias. Long-term treatment until there is evidence of disease progression may be recommended at the best-tolerated doses of both lenalidomide and dexamethasone. Recommendations regarding the prevention and management of adverse events, particularly venous thromboembolism and myelosuppression, were provided on the basis of the available evidence and practical experience of panel members. Ongoing trials will provide more insight into the effects of continuous lenalidomide-based therapy in myeloma. AB An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM). On the basis of the available evidence, the panel agreed that Len/Dex is a valid and effective treatment option for most patients with RRMM. As with other therapies, using Len/Dex at first relapse is more effective regarding response rate and durability than using it after multiple salvage therapies. Len/Dex may be beneficial regardless of patient age, disease stage and renal function, although the starting dose of lenalidomide should be adjusted for renal impairment and cytopenias. Long-term treatment until there is evidence of disease progression may be recommended at the best-tolerated doses of both lenalidomide and dexamethasone. Recommendations regarding the prevention and management of adverse events, particularly venous thromboembolism and myelosuppression, were provided on the basis of the available evidence and practical experience of panel members. Ongoing trials will provide more insight into the effects of continuous lenalidomide-based therapy in myeloma.
dcterms:title
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
skos:prefLabel
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
skos:notation
RIV/65269705:_____/11:#0001362!RIV12-MZ0-65269705
n13:predkladatel
n16:ico%3A65269705
n4:aktivita
n11:V n11:I
n4:aktivity
I, V
n4:cisloPeriodika
5
n4:dodaniDat
n9:2012
n4:domaciTvurceVysledku
n14:9622748
n4:druhVysledku
n15:J
n4:duvernostUdaju
n5:S
n4:entitaPredkladatele
n8:predkladatel
n4:idSjednocenehoVysledku
218805
n4:idVysledku
RIV/65269705:_____/11:#0001362
n4:jazykVysledku
n17:eng
n4:klicovaSlova
lenalidomide; multiple myeloma
n4:klicoveSlovo
n7:lenalidomide n7:multiple%20myeloma
n4:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n4:kontrolniKodProRIV
[7F0DFD2D893D]
n4:nazevZdroje
Leukemia
n4:obor
n6:FD
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
16
n4:rokUplatneniVysledku
n9:2011
n4:svazekPeriodika
25
n4:tvurceVysledku
Dimopoulos, M. A. Hájek, Roman
n4:wos
000290471100002
s:issn
0887-6924
s:numberOfPages
12